CA2972076A1 - Combination of raf inhibitors and aurora kinase inhibitors - Google Patents

Combination of raf inhibitors and aurora kinase inhibitors Download PDF

Info

Publication number
CA2972076A1
CA2972076A1 CA2972076A CA2972076A CA2972076A1 CA 2972076 A1 CA2972076 A1 CA 2972076A1 CA 2972076 A CA2972076 A CA 2972076A CA 2972076 A CA2972076 A CA 2972076A CA 2972076 A1 CA2972076 A1 CA 2972076A1
Authority
CA
Canada
Prior art keywords
cancer
raf
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2972076A
Other languages
English (en)
French (fr)
Inventor
Viviana BOZON
Katherine M. Galvin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA2972076A1 publication Critical patent/CA2972076A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2972076A 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors Abandoned CA2972076A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096020P 2014-12-23 2014-12-23
US62/096,020 2014-12-23
PCT/US2015/067459 WO2016106357A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2972076A1 true CA2972076A1 (en) 2016-06-30

Family

ID=56151529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2972076A Abandoned CA2972076A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors

Country Status (6)

Country Link
US (1) US20180263979A1 (enExample)
EP (1) EP3236948A4 (enExample)
JP (1) JP2018502089A (enExample)
CN (1) CN107205933A (enExample)
CA (1) CA2972076A1 (enExample)
WO (1) WO2016106357A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532065B1 (en) 2016-10-28 2024-04-24 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
WO2018204226A1 (en) * 2017-05-03 2018-11-08 St. Jude Children's Research Hospital Compositions and methods for prevention and treatment of hearing loss
EP4065122A4 (en) * 2019-11-27 2023-12-27 Day One Biopharmaceuticals, Inc. Solid dispersion of pan-raf kinase inhibitor
MX2023005303A (es) * 2020-11-06 2023-09-12 Day One Biopharmaceuticals Inc Inhibidor de raf para el tratamiento del glioma de bajo grado.
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372782A1 (en) * 1999-05-11 2000-11-16 Wing Cheung Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
CN1835756A (zh) * 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
CN101056632B (zh) * 2004-11-09 2011-12-07 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
PL1896470T3 (pl) * 2005-05-16 2011-03-31 Irm Llc Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
SG11201610534UA (en) * 2014-06-16 2017-01-27 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment

Also Published As

Publication number Publication date
CN107205933A (zh) 2017-09-26
EP3236948A4 (en) 2018-10-03
WO2016106357A1 (en) 2016-06-30
EP3236948A1 (en) 2017-11-01
JP2018502089A (ja) 2018-01-25
US20180263979A1 (en) 2018-09-20
WO2016106357A8 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
JP2021156893A (ja) Rtk突然変異細胞を有する患者を処置するための組成物及び方法
US11007184B2 (en) Cancer treatments using combinations of type 2 MEK and ERK inhibitors
JP2013543008A (ja) Braf阻害剤による治療方法
US10337004B2 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
EP3889254A1 (en) A mek1 mutation conferring resistance to raf and mek inhibitors
WO2013188355A1 (en) Cdk inhibitor for treating refractory chronic lymphocytic leukemia
AU2018309739A1 (en) Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia
JP6549147B2 (ja) Nras変異癌の処置における使用のためのegfr阻害剤とmek阻害剤の組合せ
JP7734139B2 (ja) Nrg1融合体を有するがんの治療のためのキナゾリンベースのチロシンキナーゼインヒビターの使用
US20200316067A1 (en) Combination of raf inhibitors and taxanes
GB2488028A (en) mTOR mutants as biomarkers for mTOR inhibitor treatment
EP4118237A1 (en) Methods of treating her2 mutant cancers with tucatinib
MX2014006186A (es) Capacidad de respuesta a los inhibidores de la angiogenesis.
WO2017066664A1 (en) Combination therapy including a raf inhibitor for the treatment of colorectal cancer
Ohno Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
WO2016106351A1 (en) Combination of raf inhibitors and mtor inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220314

FZDE Discontinued

Effective date: 20220314